FDA’s OPDP Warns MannKind for Facebook Post

The US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) earlier this month sent a warning letter to MannKind for a Facebook post that makes false or misleading claims about the risks associated with the company’s inhaled insulin, known as Afrezza..